norditropine simplex

Small molecule

norditropine simplex is one of 6 small molecule programs targeting Hypophosphatemic Rickets. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypophosphatemic RicketsActive, not recruiting

Hypophosphatemic RicketsPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Hypophosphatemic Rickets

#DrugCompanyPhaseTrials

Rocaltrol

Alnylam Pharmaceuticals

Approved

—2

Calciferol

Alnylam Pharmaceuticals

Approved

—3

CRYSVITA

Kyowa Kirin Co., Ltd.

Phase 3

1 4

Sensipar

Amgen

Phase 1

2 5

Renagel

GGenzyme, a Sanofi Company

Preclinical

1 6

norditropine simplex

BBicetre Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypophosphatemic Rickets1 trial

Growth Hormone Treatment in Children With Hypophosphatemic Rickets

Completed·—·Phase 1/2·NCT02720770·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for norditropine simplex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — norditropine simplex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for norditropine simplex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bicetre Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBicetre Hospital

norditropine simplex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypophosphatemic Rickets1 trial

References

Drug Info

Quick Facts

Related News